An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 11/22/2024 6:27 PM
Question 20210027
Inquiry Details
References:
Heme & Lymph Manual & DB. September 2020; Effective with Cases Diagnosed 1/1/2010 and Forward
Question:
Reportability--Heme and Lympoid Neoplasms--Polycythemia vera: Is secondary polycythemia vera reportable? See Discussion.
Discussion:
A physician stated the patient likely had secondary polycythemia vera due to cardiac and pulmonary conditions but that a polycythemia vera could not be ruled out. A JAK2 was ordered that was positive for JAK2 V617F mutation. The patient was treated with hydrea.
According to SEER SINQ 20120049, secondary polycythemia vera is not reportable. However, in this case, the patient was positive for JAK2 V617F mutation. Therefore, is this reportable? We looked for guidance in the Hematopoietic and Lymphoid Neoplasms Database and found it confusing that secondary polycythemia vera was not mentioned or discussed under polycythemia vera in the database. The only thing we could find was secondary polycythemia NOS that was discussed under polycythemia.
Answer:
Abstract as a new primary for polycythemia vera, 9950/3.
JAK2 is commonly used to assess suspected polycythemia vera and in this case, the mutation is positive for V617F.
Based on the JAK2 results, this looks like a true polycythemia vera and not a secondary polycythemia.
